Strong financial position with $371.6 million in cash, cash equivalents and marketable securities expected to support operations into 2026
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NMRA:
- Neumora Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
- 3 Best Stocks to Buy Now, 7/23/2024, According to Top Analysts
- Neumora Therapeutics initiated with a Buy at Needham
- Neumora Therapeutics initiated with an Outperform at Mizuho
- Neumora Therapeutics announces initiation of Phase 1b study of NMRA-511